E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Heart failure with reduced ejection fraction |
Insuficiencia cardíaca con fracción de eyección reducisa |
|
E.1.1.1 | Medical condition in easily understood language |
Heart failure |
Insuficiencia cardiaca |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10019279 |
E.1.2 | Term | Heart failure |
E.1.2 | System Organ Class | 100000004849 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to continue to evaluate the safety and tolerability of LCZ696 in heart failure patients from PARADIGM-HF receiving open-label investigational drug. |
El objetivo principal de este estudio es continuar evaluando la seguridad y la tolerabilidad de LCZ696 en pacientes con insuficiencia cardíaca del estudio PARADIGM-HF que reciben tratamiento abierto con el fármaco en investigación. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Written informed consent for the extension must be obtained before any assessment is performed. 2. Patients who have completed PARADIGM-HF (protocol CLCZ696B2314) and are able to be safely enrolled into the open-label trial as judged by the investigator. |
1. Deberá obtenerse el consentimiento informado por escrito para la extensión antes de que se realice ninguna evaluación. 2. Pacientes que hayan finalizado el estudio PARADIGM-HF y puedan realizar con seguridad la transición al estudio abierto a criterio del investigador. |
|
E.4 | Principal exclusion criteria |
1. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer 2. History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACEIs, ARBs, or NEP inhibitors as well as known or suspected contraindications to LCZ696 3. Known history of angioedema 4. Requirement of simultaneous treatment with both ACEIs and ARBs 5. Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy) 6. Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 (screening) 7. Estimated GFR < 30 mL/min/1.73m2 as measured by the simplified MDRD formula at Visit 1 (screening) 8. Presence of bilateral renal artery stenosis 9. Serum potassium > 5.2mmol/L at Visit 1 (screening) 10. Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 3 x ULN at Visit 1, history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt 11. Pregnant or nursing (lactating) women 12. Women of childbearing potential 13. Any condition, not identified in the protocol, that in the opinion of the investigator is likely to prevent the patient from safely tolerating LCZ696 or complying with the requirements of the study. |
1. Uso de otros medicamentos en investigación en el momento de la inclusión, o en el plazo de 30 días o 5 semividas previos al reclutamiento, lo que sea más largo. 2. Antecedentes de hipersensibilidad o alergia a algún fármaco del estudio, fármacos de grupos químicos similares, IECA, ARA o inhibidores de la EPN así como contraindicaciones presuntas o conocidas a LCZ696. 3. Antecedentes conocidos de angioedema. 4. Necesidad de tratamiento simultáneo con IECA y ARA. 5. IC aguda descompensada actual (exacerbación de una IC crónica manifestada por signos y síntomas que puedan requerir tratamiento intravenoso). 6. Hipotensión sintomática y/o PAS < 100 mmHg en la visita 1 (selección). 7. FG estimada < 30 ml/min/1,73 m2 calculada mediante la fórmula MDRD simplificada en la visita 1 (selección) 8. Presencia de estenosis de la arteria renal bilateral 9. Potasio sérico > 5,2 mmol/l en la visita 1 (selección) 10. Signos de hepatopatía determinada por una de las siguientes circunstancias: Valores de AST o ALT > 3 x LSN en la visita 1, antecedentes de encefalopatía hepática, antecedentes de varices esofágicas o antecedentes de derivación portocava. 11. Mujeres embarazadas o en lactación, definido el embarazo como el estado de la mujer desde la concepción hasta el final de la gestación, confirmado por un resultado positivo en el análisis de HCG (> 5 mUI/ml). 12. Mujeres en edad fértil, definidas como las que tengan capacidad fisiológica de quedarse embarazadas 13. Cualquier trastorno que, en opinión del investigador, pueda impedir que el paciente tolere de forma segura LCZ696 o cumplir los requisitos del estudio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary assessments for safety are the reporting of angioedema, AEs that are suspected to be related to LCZ696, AEs leading to study drug discontinuation and serious adverse events (SAE) including death. The assessment of safety will be based primarily on the frequency of adverse events of special interest, sitting systolic and diastolic blood pressure, heart rate, and serious adverse events suspected by the investigators to be related to LCZ696 for the Safety set. |
La evaluación principal de la seguridad es la notificación de angioedema, AA que se sospeche que están relacionados con LCZ696, AA que provoquen la suspensión del fármaco del estudio y los acontecimientos adversos graves (AAG), incluida la muerte. La evaluación de la seguridad se basará fundamentalmente en la frecuencia de los acontecimientos adversos de interés especial, presión arterial sistólica y diastólica en sedestación, frecuencia cardíaca y acontecimientos adversos graves que los investigadores sospechen que están relacionados con LCZ696 en el grupo de seguridad. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Total follow up time (up to 30 months) |
Tiempo de seguimiento total (hasta 30 meses) |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Safety and tolerability of LCZ696 in patients with chronic heart failure |
Seguridad y tolerabilidad del LCZ696 en pacientes con insuficiencia cardíaca crónica |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 17 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 429 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Belgium |
Brazil |
Bulgaria |
Canada |
Chile |
China |
Colombia |
Czech Republic |
Denmark |
Dominican Republic |
Ecuador |
Estonia |
Finland |
France |
Germany |
Guatemala |
Hong Kong |
Hungary |
Iceland |
India |
Israel |
Italy |
Korea, Republic of |
Latvia |
Lithuania |
Malaysia |
Mexico |
Netherlands |
Panama |
Peru |
Philippines |
Poland |
Romania |
Russian Federation |
Singapore |
Slovakia |
South Africa |
Spain |
Sweden |
Taiwan |
Thailand |
Turkey |
United Kingdom |
United States |
Venezuela, Bolivarian Republic of |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Expected LVLS: 2017-03-31 |
LVLS estimado; 31-03-2017 |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |